GP
CRL icon

Girard Partners’s Charles River Laboratories CRL Stock Holding History

Girard Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$5.7M Buy
27,594
+97
+0.4% +$22K 0.54% 47
2024
Q1 		$7.45M Buy
27,497
+2,566
+10% +$613K 0.7% 36
2023
Q4 		$5.89M Buy
24,931
+3,175
+15% +$624K 0.6% 40
2023
Q3 		$4.26M Buy
21,756
+1,076
+5% +$221K 0.48% 50
2023
Q2 		$4.35M Buy
+20,680
New +$4.11M 0.46% 52

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Girard Partners's CRL Position: Q2 2024 in Review

Girard Partners increased its Charles River Laboratories (CRL) stake by 0.35% in Q2 2024, buying an estimated $22K and bringing the position to 27,594 shares worth $5.7M. The position accounts for 0.54% of the portfolio, ranked #47.

Girard Partners first reported a position in CRL in Q2 2023 and has held it in 5 quarters since. The position peaked at $7.45M in Q1 2024. 664 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • Girard Partners held 27,594 shares of Charles River Laboratories worth $5.7M as of Q2 2024.
  • Girard Partners bought 97 Charles River Laboratories shares in Q2 2024, an estimated $22K.
  • Charles River Laboratories made up 0.54% of Girard Partners's portfolio in Q2 2024, its #47 holding.
  • Girard Partners first reported a position in Charles River Laboratories in Q2 2023 and has held it in 5 quarters since.
  • Girard Partners's Charles River Laboratories position peaked at $7.45M in Q1 2024.
  • 664 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Girard Partners's 13F filing for Q2 2024, filed 12 Aug 2024.